To provide young scholars with an active academic exchange platform for exchanging ideas with each other and with influential experts in cancer metastasis and treatment, and cultivate candidates for Editorial Board of Journal of Cancer Metastasis and Treatment(JCMT), the Editorial Office plans to recruit youth Editorial Board members worldwide from now on. This project is planned to be completed by February 28, 2021.
The followings are qualifications, responsibilities and benefits as well as the journal information for your reference.
JCMT was launched with Dr. Lucio Miele as the Editor-in-Chief, which has a strong Editorial Board. Under the supports of our Editorial Board members, authors and reviewers, adhering to high-quality publishing, JCMT has been striving for five years and will continue moving forward. JCMT has made very good progress:
Many internationally recognized researchers joined the Editorial Board:
Prof. Hans-Joachim Schmoll (University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany);
Prof. Jesus San-Miguel ( Clinica Universitaria de Navarra, Pamplona, Spain);
Prof. Fred R. Hirsch (Clinical Institute for Lung Cancer, Mount Sinai Cancer, Mount Sinai Health System, Tisch Cancer Institute, Icahn School of Medicine, USA);
Prof. Jörg Kleeff (Department of Surgery, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany);
Prof. Jan B. Vermorken (Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium);
Prof. Massimo Federico (Medical Oncology, CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy);
Know about more new Editorial Board members: https://jcmtjournal.com/editorsChief/index.
Many internationally recognized researchers have contributed manuscripts to the journal:
Prof. Malcolm Mason (Getting better at treating prostate cancer: what clinicians should want from scientists: https://jcmtjournal.com/article/view/2287);
Prof. Annamaria Colao (Pancreatic neuroendocrine tumor with hypoglycemia and elevated insulin-like growth factor II: a case report: https://jcmtjournal.com/article/view/1586);
Prof. Richard Sylvester (Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more: https://jcmtjournal.com/article/view/2157);
Prof. Rafael Rosell (PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer: https://jcmtjournal.com/article/view/3018);
Prof. Massimo Falconi (Management of hepatic metastases of well/moderately differentiated neuroendocrine tumors of the digestive tract: https://jcmtjournal.com/article/view/1556);
Prof. Rodolfo Montironi (Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review: https://jcmtjournal.com/article/view/3177);
Find more high-quality publications: https://jcmtjournal.com/journal/archives.
Many internationally recognized researchers have helped review submissions for the journal:
Prof. Claudia Turro;
Prof. Sandhya Pruthi;
Prof. Daniel E. Johnson;
Prof. Gautam Sethi;
Prof. Laurence H. Baker;
Prof. John Healey;
The publications in JCMT have still been widely cited in the situation of not applying for the important databases (like PubMed, Scopus, ESCI) and having low exposure. As of October 10, 2020, the calculated impact factor for 2020 has been 1.5, which is expected to exceed 2 by the end of the year. Welcome to check the citation information of articles published in 2018 and 2019.
The Editorial Office is currently working on database application including PubMed, Scopus and ESCI, with the belief of achieving success based on the solid accumulation over the past years. More researchers will know the journal and read the high-quality articles on the journal after these databases indexing. The first target impact factor of JCMT is 5.
Welcome to send your CV to firstname.lastname@example.org and work together to realize the establishment of an influential academic journal in the field of cancer metastasis and treatment.